What’s The Deal With Sarepta?

It’s been a wild ride so far this year for shareholders of Sarepta Therapeutics Inc SRPT 2.71%. The year got off to a disastrous start back in January when the stock plummeted 55 percent in a single trading day after the FDA released advisory committee briefing documents that were highly critical of the company’s leading…